A Phase 1/2 interventional study of VTRU200 in Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) and High Risk Myelodysplastic Syndrome, sponsored by Vitruviae. Not yet recruiting. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Vitruviae · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
About this study
This is the first study of VTRU200 in people. The main purpose of this study is to find a safe dose of VTRU200 and learn how the medicine behaves in the body. Researchers will also look for early signs that it may help treat cancer.
VTRU200 is an experimental immunotherapy. It is designed to help the body's immune system find and destroy cancer cells while limiting effects on healthy cells.
Unlike many cancer treatments that target a single protein, VTRU200 recognizes stress signals that are commonly found on cancer cells. These signals include certain sugars (called glycans) and fats (called phospholipids) that are present on many types of cancer cells but are uncommon on normal healthy cells. VTRU200 also attaches to immune cells called T cells and helps direct them to attack cancer cells.
Because VTRU200 targets features that are shared by many cancers, it may continue to work even if cancer cells lose or change individual proteins that other treatments depend on.
Who can take part?
This study is for people with certain blood cancers that have come back after treatment or have not responded to available treatments. These include:
Acute myeloid leukemia (AML) Higher-risk myelodysplastic syndromes (HR-MDS) Diffuse large B-cell lymphoma (DLBCL) that has returned after CAR T-cell therapy
Later parts of the study may also include adolescents and children with AML.
What will happen during the study?
Participants will receive VTRU200 through a vein (intravenous infusion).
The study will begin by giving small doses to help determine the safest dose for future participants. If those doses are well tolerated, later participants may receive higher doses.
Researchers will:
Monitor participants closely for side effects. Perform blood tests to measure how VTRU200 moves through and leaves the body. Measure how the immune system responds to treatment. Check whether the cancer shrinks, disappears, or remains under control.
Participants may receive multiple treatment cycles if they continue to benefit and do not have unacceptable side effects.
What are the possible benefits?
VTRU200 may or may not help participants. Information learned from this study may help develop new treatments for people with these cancers in the future.
What are the possible risks?
Because VTRU200 is being tested in humans for the first time, not all side effects are known.
Possible risks include reactions related to activation of the immune system, infusion-related reactions, laboratory test changes, and other side effects. Participants will be monitored closely throughout the study, and medical care will be available if side effects occur.
Brief Study Description
This first-in-human, open-label, Phase 1/2a study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of VTRU200 in participants with relapsed or refractory acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (HR-MDS), or diffuse large B-cell lymphoma (DLBCL) following CAR T-cell therapy. VTRU200 is an investigational trispecific T-cell engager that binds stress-associated glycans, phosphatidylserine, and CD3 to redirect T cells toward cancer cells. The Phase 1 dose-escalation portion will determine the recommended Phase 2 dose (RP2D), followed by disease-specific expansion cohorts to further evaluate safety and preliminary antitumor activity.
Why is this research important?
Many blood cancers eventually stop responding to available treatments. Cancer cells can escape therapy by changing or losing the proteins that many current medicines target.
VTRU200 is designed to recognize stress-related features that many cancer cells share rather than relying on a single protein target. Researchers hope this approach may reduce the chance of treatment resistance while limiting damage to healthy cells. This study will help determine whether VTRU200 can be given safely and whether it shows early signs of helping people with difficult-to-treat blood cancers.
Relapsed or refractory (R/R) acute myeloid leukemia (AML), higher-risk myelodysplastic syndromes (HR-MDS), and diffuse large B-cell lymphoma (DLBCL) after chimeric antigen receptor (CAR) T-cell therapy remain associated with poor clinical outcomes despite recent therapeutic advances. Although targeted therapies and immunotherapies have improved outcomes for some patients, treatment failure frequently occurs because of disease heterogeneity, antigen loss, immune escape, and treatment resistance. Therefore, novel therapeutic approaches capable of recognizing shared cancer-associated features across genetically diverse tumors are needed.
VTRU200 is a first-in-class, investigational trispecific T-cell engager (TCE) designed to redirect endogenous T cells toward malignant cells through simultaneous binding of CD3 on T cells and two stress-associated tumor surface markers: aberrant high-mannose glycans and phosphatidylserine (PS). These glycan and lipid structures are enriched on many malignant cells and cells within the tumor microenvironment as a consequence of altered glycosylation, metabolic stress, oxidative stress, endoplasmic reticulum stress, impaired membrane asymmetry, rapid proliferation, and resistance to therapy. In contrast, these targets are minimally exposed on most normal healthy tissues, providing the rationale for selective tumor targeting.
Preclinical studies demonstrated that VTRU200 binds tumor cells expressing these stress-associated surface markers and mediates potent T-cell activation and cytotoxicity across multiple AML models. In nonclinical studies, VTRU200 exhibited antitumor activity in vitro and in vivo, demonstrated minimal cytokine release relative to conventional CD3-engaging therapies, showed no detectable binding to normal human peripheral blood leukocytes or hematopoietic stem and progenitor cells, and did not bind an FDA-recommended panel of normal human or cynomolgus monkey tissues. Repeat-dose animal studies demonstrated a favorable therapeutic window supporting clinical evaluation.
This is a first-in-human, multicenter, open-label Phase 1/2a study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of VTRU200 administered by intravenous infusion.
The Phase 1 dose-escalation portion will determine the maximum tolerated dose (MTD), if reached, and identify the recommended Phase 2 dose (RP2D). Dose escalation will begin with an accelerated titration design using sentinel participants at the lowest dose levels, followed by a Bayesian Optimal Interval (BOIN) design after evidence of acceptable safety. Escalation decisions will be based on predefined safety criteria and review by the Safety Review Committee.
Following determination of the RP2D, the Phase 2a dose-expansion portion will further characterize the safety profile and evaluate preliminary clinical activity in disease-specific cohorts. Adult participants with R/R AML and HR-MDS will constitute the primary efficacy population, with additional exploratory cohorts enrolling participants with DLBCL following CAR T-cell therapy failure. Adolescent and pediatric participants with AML may be enrolled after establishment of an acceptable safety profile and appropriate adult exposure.
Safety evaluations will include monitoring of adverse events, serious adverse events, infusion-related reactions, immune-mediated toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), clinical laboratory testing, vital signs, electrocardiograms, physical examinations, and concomitant medications.
PK assessments will characterize serum concentrations of VTRU200, while immunogenicity assessments will evaluate anti-drug antibodies (ADA). PD analyses will assess biomarkers of immune activation, cytokine responses, target engagement, and changes within peripheral blood and bone marrow, where applicable.
Preliminary antitumor activity will be evaluated using disease-specific response criteria, including the European LeukemiaNet (ELN) recommendations for AML, International Working Group (IWG) criteria for HR-MDS, and Lugano Classification criteria for DLBCL. Additional efficacy endpoints include measurable residual disease (MRD), duration of response, progression-free survival, overall survival, and other clinically relevant measures of disease control.
This study is designed primarily to establish the safety profile, appropriate dose, and biologic activity of VTRU200 while providing an initial assessment of its clinical activity in patients with relapsed or refractory hematologic malignancies for whom effective treatment options remain limited.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
This study's planned enrollment of 108 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →This is the only study on the registry with Vitruviae as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
I. confirmed acute myeloid leukemia (AML) according to WHO 2022 criteria. AML, defined as either:
III. DLBCL post-CAR T: histologically confirmed DLBCL per WHO 2022 criteria and relapsed or refractory disease after prior CART therapy. Qualifying post-CAR T treatment failure must be documented at least 1 month after CAR T infusion and include no metabolic response, first metabolic progressive disease, or first relapse after prior response. Prior CART infusion must have occurred at least 1 month before screening. Participants must not be in partial metabolic response or complete metabolic response at screening and must have on PET/CT (preferred) or CT/MRI, defined as at least 1 nodal lesion >1.5 cm or at least 1 extranodal lesion >1.0 cm; if PET is used, lesions must be FDG-avid and consistent with active lymphoma IV. Advanced solid tumors 2. Children (6 months-11 years) and adolescents (12-17 years) with R/R-AML.
Children and adolescent relapsed AML: A single bone marrow sample showing 5% leukemic blasts by MFC, fluorescence in situ hybridization (FISH) testing or other molecular method, or a single bone marrow sample with at least two tests showing 1% blasts such as by MFC, karyotypic abnormality with at least one metaphase similar or identical to diagnosis, FISH abnormality identical to one present at diagnosis (above level of sensitivity of specific FISH probe) or polymerase chain reaction (PCR) or next generation sequencing (NGS)-based demonstration of leukemogenic lesion (e.g., fusion, mutation) identical to diagnosis and is quantifiably 1% 3. (ECOG) performance status 0-2 or Performance Score (KPS) ≥50% 4. Adequate organ function: I. Hepatic: Serum /ALT ≤2.5× and total ≤1.5×ULN (≤3×ULN if Gilbert's syndrome) II. Renal: Serum creatinine ≤1.5×ULN; Calculated : ≥40 mL/min (Cockcroft-Gault [adults]; Schwartz formula [adolescents]; apply if serum creatinine is borderline) III. Cardiac: ≥ 50% and no evidence of pericardial effusion as determined by ECHO IV. Hematologic: WBC count must be ≤20 × 10⁹/L prior to the first dose of study treatment and before each dose in Cycle 1; patients with WBC >20 × 10⁹/L may receive cytoreduction with hydroxyurea (up to 4 g/day) and/or leukapheresis per protocol to achieve this threshold, with hydroxyurea held ≥12-24 hours before each study treatment dose 5. Females of must have a negative serum or urine pregnancy test 6. Adults: written . Adolescents: written patient assent plus parental/guardian informed consent.
7. Prior treatment with an agent is permitted provided that at least 5 half-lives have elapsed and all treatment-related toxicities have resolved to Grade ≤1 (except alopecia). Prior T-cell engaging, , or cellular therapies require a minimum of 8 weeks.
Exclusion Criteria:
1. Active central nervous system (CNS) disease requiring treatment. 2. Uncontrolled or baseline neurologic disorder (e.g., uncontrolled seizures or severe cognitive impairment/delirium), significant psychiatric illness or active substance abuse.
3. Uncontrolled infections including persistent bacteremia/fungemia despite appropriate therapy, progressive invasive fungal infection, or uncontrolled viral infection with end-organ disease. Active tuberculosis.
4. Concurrent requiring active systemic therapy. 5. Cytotoxic chemotherapy within 14 days prior to first dose. Targeted anti-leukemic therapy within 7-14 days prior to first dose. Radiotherapy within 14 days prior to first dose (except limited-field palliative radiotherapy). Prior CD3-engaging therapy.
6. T-cell depleting therapy (ATG, alemtuzumab, or equivalent) within 6 months prior to enrollment 7. Severe uncontrolled cardiovascular disease (e.g., class III/IV heart failure, unstable angina or MI within 6 months, uncontrolled arrhythmia). Severe uncontrolled pulmonary disease (e.g., requiring high-flow oxygen or ventilatory support).
8. Systemic >10 mg/day prednisone equivalent within 7 days prior to first dose.
9. Active disease requiring systemic within the past 12 months.
10. Prior transplant within 3 months or active (GVHD).
11. Primary immunodeficiency (congenital immunodeficiency disorder requiring ongoing medical management).
12. Known infection. : HBsAg positive (chronic HBV infection). : anti-HCV positive (HCV exposure).
13. Pregnant or breastfeeding 14. Known congenital or acquired bleeding disorder, including hemophilia A/B or von Willebrand disease, or other clinically significant coagulopathy 15. History of severe allergic reaction to immunotherapy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ARM A: Adult R/R AML and HR-MDS; VTRU200 infusion
Biological: VTRU200
Adult DLBCL post-CAR T failure; VTRU200 infusion
Biological: VTRU200
Adolescent R/R AML with no curative option (12-17 years); VTRU200 infusion
Biological: VTRU200
Expansion at RP2D-Adult R/R AML and HR-MDS; VTRU200 infusion
Biological: VTRU200
Expansion at RP2D: Adult DLBCL post-CAR T failure
Biological: VTRU200
Expansion at RP2D: Adolescent R/R AML with no curative option; VTRU200 infusion
Biological: VTRU200
Expansion at RP2D: Adult solid cancers; VTRU200 infusion
Biological: VTRU200
Expansion at RP2D: Pediatric R/R AML (6 months-11 years) ; VTRU200 infusion
Biological: VTRU200
VTRU200 is an investigational humanized trispecific T-cell engager administered by intravenous infusion. It binds CD3 on T cells and tumor associated glycans and lipids to redirect T-cell cytotoxicity toward malignant cells. Multiple dose levels will be evaluated during dose escalation to determine safety and the recommended Phase 2 dose.
Phase 1: Safety and tolerability
Incidence and severity of treatment-emergent AEs (number and percentage)
Time frame: 28 days
Phase 1: Safety and tolerability
Incidence of serious adverse events (number and percentage)
Time frame: 28 days
Phase 1: Pharmacokinetics
Time frame: 6 months
Phase 1: Safety and tolerability
Incidence of dose-limiting toxicities
Time frame: 28 days
Phase 1: Determination of RP2D
Integrated assessment of safety, PK, PD and preliminary disease-specific evidence of biological activity (e.g., reduction in bone marrow blast percentage, peripheral blood blast clearance, hematologic recovery, or reduction in measurable tumor burden
Time frame: 6 months
Phase 2a: Efficacy
Adult AML: Durable CR and durable CR+CRh (ELN criteria)
Time frame: 12 months
Phase 2a: Efficacy
HR-MDS: Durable CR and CR+PR (IWG criteria)
Time frame: 12 months
Phase 2a: Efficacy
DLBCL: ORR (Lugano Classification)
Time frame: 12 months
Phase 2a- Preliminary Efficacy
Advanced solid tumors: ORR (RECIST v1.1)
Time frame: 12 months
Phase 2a: Safety and tolerability
Treatment-emergent adverse events (Incidence and percentage)
Time frame: 24 months
Phase 1: Preliminary Efficacy
Complete remission (CR) rate in AML
Time frame: 6 months
Phase 1- Preliminary Efficacy
Composite overall response rate (ORR = CR + CRh + CRi + MLFS + PR) in AML
Time frame: 6 months
Phase 1- Preliminary Efficacy
Minimal residual disease (MRD) negativity rate (\<0.01%) in AML
Time frame: 6 months
Phase 1- Preliminary Efficacy
Duration of response (DoR) in AML responders
Time frame: 24 months
Phase 1- Preliminary Efficacy
Complete remission (CR) rate in high-risk MDS
Time frame: 6 months
Phase 1- Preliminary Efficacy
Overall response rate in high-risk MDS
Time frame: 6 months
Phase 1- Preliminary Efficacy
Duration of response (DoR) in high-risk MDS
Time frame: 24 months
Phase 1- Preliminary Efficacy
Overall response rate (ORR) in DLBCL
Time frame: 6 months
Phase 1- Preliminary Efficacy
Duration of response (DoR) in DLBCL
Time frame: 6 months
Phase 1- Preliminary Efficacy
Overall response rate (ORR) in advanced solid tumors
Time frame: 6 moths
Phase 1- Preliminary Efficacy
Disease control rate (DCR) in advanced solid tumors
Time frame: 6 months
Phase 1- Preliminary Efficacy
Duration of response (DoR) in advanced solid tumors
Time frame: 24 months
Phase 1- Preliminary Efficacy
Composite overall response rate (ORR) in pediatric AML
Time frame: 6 months
Phase 1- Preliminary Efficacy
Minimal residual disease (MRD) negativity rate (\<0.01%) in pediatric AML
Time frame: 6 months
Phase 1- Incidence of Anti-drug Antibodies
Incidence of Anti-drug Antibodies
Time frame: 6 months
Phase 1- Preliminary Efficacy
Complete remission (CR) rate in AML
Time frame: 6 months
Phase 2a: Safety and tolerability
Treatment-related adverse events (Incidence and percentage)
Time frame: 24 months
Phase 2a: Safety and tolerability
Serious adverse events (Incidence and percentage)
Time frame: 24 months
Phase 2a- Efficacy
Composite overall response rate (ORR = CR + CRh + CRi + MLFS + PR) in AML
Time frame: 6 months
Phase 2a- Exploratory
Change from baseline in tumor-reactive T-cell clonal expansion
Time frame: 24 months
Phase 2a- Exploratory
Persistence of tumor-reactive T-cell clones
Time frame: 24 months
Phase 2a- Exploratory
Change from baseline in PD-1 expression
Time frame: 24 months
Phase 2a- Exploratory
Change from baseline in IDO1 expression
Time frame: 24 months
Phase 2a- Exploratory
Change from baseline in myeloid-derived suppressor cell (MDSC) frequency
Time frame: 24 months
Phase 2a- Exploratory
Change from baseline in regulatory T-cell (Treg) frequency
Time frame: 24 months
Phase 2a- Exploratory
Change from baseline in extracellular vesicle phosphatidylserine (PS) expression
Time frame: 24 months
Phase 2a- Exploratory
Change from baseline in extracellular vesicle high-mannose glycan (Man9) expression
Time frame: 24 months
No study locations are listed for this record.
Plan to share: Undecided — The sponsor has not yet determined whether de-identified individual participant data (IPD) collected during this study will be shared with other researchers. Any future data-sharing decisions will consider participant privacy, informed consent, applicable laws and regulations, protection of confidential and proprietary information, and scientific and regulatory considerations.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.
Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 12 months is below that.
Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.